Grand Pharmaceutical Group Limited (HK:0512) has released an update.
Grand Pharmaceutical Group Limited has successfully acquired 100% equity interests in Tianjin Tanabe and Baiji Pharmaceutical, aiming to strengthen its position in the cerebro-cardiovascular and respiratory disease sectors. The total purchase for Tianjin Tanabe was approximately RMB 488 million, transforming it into a wholly-owned subsidiary and a new growth point in the company’s strategic plan. This move is set to enhance the Group’s market competitiveness in chronic disease treatments amidst China’s growing demand due to an aging population.
For further insights into HK:0512 stock, check out TipRanks’ Stock Analysis page.
